Company intelligence / Profile preview

ÅKERS

Thorofare, New Jersey, United Statesuniones.com ↗

Ownership: Private
Employees: ~13
Development stage: Commercial

Overview

Akers Biosciences developed proprietary rapid diagnostic tests for health and infectious diseases and pursued a virus-like particle-based COVID‑19 vaccine in partnership with Premas Biotech. Its pipeline included small molecule drugs for pain and rheumatoid arthritis targeting CB2 receptor agonists and TNF‑α modulators. The company’s main clinical programs were in preclinical or early clinical stages as of the latest available information.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Small moleculeVaccineVirus-like particle (VLP) vaccine
Industry: Biotech

Partnerships

Premas Biotech [COVID–19 VLP vaccine development partner]

Beyond the preview

Go deeper on ÅKERS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ÅKERS.

Explore the full profile